Endocannabinoids and liver disease. IV. Endocannabinoid involvement in obesity and hepatic steatosis.
about
Orphan endogenous lipids and orphan GPCRs: a good matchCannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosisThe endocannabinoid system: potential for reducing cardiometabolic riskHigh tumour cannabinoid CB1 receptor immunoreactivity negatively impacts disease-specific survival in stage II microsatellite stable colorectal cancer.Liquid chromatography-mass spectrometry-based parallel metabolic profiling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver disease.Treatment options for nonalcoholic Fatty liver diseaseProtective role of cannabinoid receptor 2 activation in galactosamine/lipopolysaccharide-induced acute liver failure through regulation of macrophage polarization and microRNAs.Global deletion of MGL in mice delays lipid absorption and alters energy homeostasis and diet-induced obesity.Increased nitroxidative stress promotes mitochondrial dysfunction in alcoholic and nonalcoholic fatty liver disease.Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitationsMonoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels.Molecular mechanisms of alcoholic fatty liverCB1 cannabinoid receptor inhibition: promising approach for heart failure?Hepatic endothelin-1 and endocannabinoids-dependent effects of hyperleptinemia in nonalcoholic steatohepatitis-cirrhotic rats.Inhibiting CB1 receptors improves lipogenesis in an in vitro non-alcoholic fatty liver disease model.Anti-inflammatory cannabinoids in diet: Towards a better understanding of CB(2) receptor action?Expression of the cannabinoid system in muscle: effects of a high-fat diet and CB1 receptor blockade.Re-visiting the Endocannabinoid System and Its Therapeutic Potential in Obesity and Associated Diseases.
P2860
Q24657799-29CCC06A-A301-48B1-8AE5-8A778FDF04AEQ33464957-4CB52DE1-226D-46CC-BC7E-BEAA427209DAQ33999727-F890D685-2DE9-412B-95C4-35F121A8CAE5Q34013690-9CCA78DF-44E8-4A56-A48D-AD876698C746Q34103693-12988AE8-E609-4D49-8774-4C69D7FECCF9Q34156317-1AF882B3-F625-4BB6-B73D-73F5B2BA979FQ35531807-5ED92EEE-C4DD-4ED4-AFB0-A636AF9D2D22Q35642904-D39B73B0-7E6E-482E-BEDA-98C47929F42DQ36831136-C6B4F404-9039-41FB-A527-5785854983F9Q36940347-3C74E30A-F64A-4A62-A95C-D5B69618865AQ36995471-FA4502ED-F159-4FC7-A9EA-394BF76C9C62Q37078754-3075833E-CE5F-416E-9EA0-3F829660D550Q37160279-AF17CA9B-F02A-4007-A614-A352AF4261FBQ38329346-4CA0DD70-D048-406D-81AC-A8ECDC13C1DEQ38939502-90ED9EAE-4484-470E-A410-2834200E6495Q43190361-8D06929A-1F1E-4459-8FDE-2D9ABAEC2D30Q43824173-143BB83B-3EE0-4DF3-9191-8655EBC23007Q47797514-E46383E4-9941-4724-990A-F040BE8EDE27
P2860
Endocannabinoids and liver disease. IV. Endocannabinoid involvement in obesity and hepatic steatosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Endocannabinoids and liver dis ...... obesity and hepatic steatosis.
@en
Endocannabinoids and liver dis ...... obesity and hepatic steatosis.
@nl
type
label
Endocannabinoids and liver dis ...... obesity and hepatic steatosis.
@en
Endocannabinoids and liver dis ...... obesity and hepatic steatosis.
@nl
prefLabel
Endocannabinoids and liver dis ...... obesity and hepatic steatosis.
@en
Endocannabinoids and liver dis ...... obesity and hepatic steatosis.
@nl
P2860
P356
P1476
Endocannabinoids and liver dis ...... obesity and hepatic steatosis.
@en
P2093
George Kunos
P2860
P304
P356
10.1152/AJPGI.00057.2008
P577
2008-02-21T00:00:00Z